Inhibitex to Present at Two Upcoming Conferences
ATLANTA--(BUSINESS WIRE)--Mar 8, 2010 - Inhibitex, Inc. (Nasdaq: INHX), today announced that Russell H. Plumb, President and Chief Executive Officer, is scheduled to present an overview of the company and its pipeline of differentiated antiviral compounds at the following two conferences:
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing products to treat serious infectious diseases. The Company's pipeline includes FV-100, which is in Phase II clinical development, for the treatment of shingles and INX-189, a nucleotide polymerase inhibitor for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development, and has licensed the use of its proprietary MSCRAMM® protein technology to Pfizer for the development of staphylococcal vaccines. For additional information about the Company, please visit www.inhibitex.com.
Inhibitex® and MSCRAMM® are registered trademark of Inhibitex, Inc.
Contact: Inhibitex, Inc.
Russell H. Plumb, 678-746-1136
Chief Executive Officer
Posted: March 2010